Telomir Pharmaceuticals (TELO) Competitors $2.65 -0.24 (-8.30%) Closing price 04:00 PM EasternExtended Trading$2.64 0.00 (-0.19%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. ORKA, RVNC, KMDA, SANA, SNDL, UPB, RAPP, STOK, RGNX, and MREOShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Oruka Therapeutics (ORKA), Revance Therapeutics (RVNC), Kamada (KMDA), Sana Biotechnology (SANA), SNDL (SNDL), Upstream Bio (UPB), Rapport Therapeutics (RAPP), Stoke Therapeutics (STOK), REGENXBIO (RGNX), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Oruka Therapeutics Revance Therapeutics Kamada Sana Biotechnology SNDL Upstream Bio Rapport Therapeutics Stoke Therapeutics REGENXBIO Mereo BioPharma Group Telomir Pharmaceuticals (NASDAQ:TELO) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership. Is TELO or ORKA more profitable? Oruka Therapeutics' return on equity of -24.96% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -1,170.58% -832.67% Oruka Therapeutics N/A -24.96%-21.22% Which has more risk & volatility, TELO or ORKA? Telomir Pharmaceuticals has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TELO or ORKA? 56.4% of Oruka Therapeutics shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer TELO or ORKA? Oruka Therapeutics received 15 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformTelomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo VotesOruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo Votes Do analysts rate TELO or ORKA? Telomir Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 466.04%. Oruka Therapeutics has a consensus price target of $39.86, indicating a potential upside of 440.80%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has preferable earnings & valuation, TELO or ORKA? Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.58-4.57Oruka TherapeuticsN/AN/A-$5.34M-$5.79-1.27 Does the media favor TELO or ORKA? In the previous week, Oruka Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Oruka Therapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Oruka Therapeutics' score of 1.13 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Telomir Pharmaceuticals Very Positive Oruka Therapeutics Positive SummaryOruka Therapeutics beats Telomir Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Remove Ads Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.87M$6.09B$5.17B$7.37BDividend YieldN/A3.02%5.35%4.25%P/E Ratio-4.576.5021.7617.54Price / SalesN/A203.67351.7989.68Price / CashN/A65.6738.1534.64Price / Book132.505.456.163.81Net Income-$16.53M$141.10M$3.19B$247.05M7 Day Performance-6.69%-3.35%-3.87%-3.50%1 Month Performance-37.35%-13.17%-2.66%-8.42%1 Year Performance-65.54%-19.80%3.36%-6.46% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.3205 of 5 stars$2.65-8.3%$15.00+466.0%-57.8%$78.87MN/A-4.571ORKAOruka Therapeutics2.9886 of 5 stars$10.26-17.9%$39.86+288.5%N/A$384.15MN/A-1.64N/ANews CoveragePositive NewsGap DownRVNCRevance Therapeutics1.901 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500KMDAKamada3.4927 of 5 stars$6.61-2.1%$14.67+121.9%+13.8%$379.94M$160.95M23.61360SANASana Biotechnology2.7022 of 5 stars$1.68-1.8%$10.80+542.9%-83.4%$378.04MN/A-1.20380Gap UpHigh Trading VolumeSNDLSNDL3.5273 of 5 stars$1.41-2.8%$3.63+157.1%-33.5%$370.51M$920.45M-4.55580News CoverageUPBUpstream BioN/A$6.12-10.9%$56.50+823.2%N/A$368.51M$2.37M0.0038Lockup ExpirationNews CoveragePositive NewsGap DownRAPPRapport Therapeutics1.6923 of 5 stars$10.03-0.2%$35.00+249.0%N/A$366.06MN/A-0.72N/AAnalyst ForecastNews CoverageGap DownSTOKStoke Therapeutics3.0711 of 5 stars$6.65-7.8%$24.67+270.9%-50.0%$359.62M$36.56M-3.17100Analyst ForecastGap DownRGNXREGENXBIO4.6394 of 5 stars$7.15-8.7%$32.78+358.4%-68.9%$358.12M$83.33M-1.42370Positive NewsGap DownMREOMereo BioPharma Group2.6075 of 5 stars$2.25-2.2%$7.71+242.9%-39.3%$349.08M$1M-37.5040Analyst Forecast Remove Ads Related Companies and Tools Related Companies Oruka Therapeutics Alternatives Revance Therapeutics Alternatives Kamada Alternatives Sana Biotechnology Alternatives SNDL Alternatives Upstream Bio Alternatives Rapport Therapeutics Alternatives Stoke Therapeutics Alternatives REGENXBIO Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TELO Stock Free TELO Stock Alerts